Search

Your search keyword '"Seror, Olivier"' showing total 334 results

Search Constraints

Start Over You searched for: Author "Seror, Olivier" Remove constraint Author: "Seror, Olivier"
334 results on '"Seror, Olivier"'

Search Results

2. Patch-based field-of-view matching in multi-modal images for electroporation-based ablations

4. Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments.

8. OS-110 ARMCENVIN: multibipolar radiofrequency ablation of HCC using intratumourous versus extratumourous “no-touch” techniques. French multicentric randomized controlled trial (NCT 01008657)

9. THU-459-YI Long-term oncological results of percutaneous radiofrequency ablation for intrahepatic cholangiocarcinoma: a multicentric retrospective study

10. OS-077 Added value of a combination of positron emission tomography with 18F-FDG and 18 F-Fluorocholine for staging optimization and treatment modification in patients with hepatocellular carcinoma: the prospective multicentric PET HCC01 study

11. THU-487-YI Upfront multi-bipolar radiofrequency ablation for hepatocarcinoma in transplant-eligible cirrhotic patients with salvage transplantation in case of recurrence

14. Health-related quality of life in locally advanced hepatocellular carcinoma treated by either radioembolisation or sorafenib (SARAH trial)

15. Cost-Utility Analysis of Transarterial Radioembolization With Yttrium-90 Resin Microspheres Compared With Sorafenib in Locally Advanced and Inoperable Hepatocellular Carcinoma

16. Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area

18. Long‐term oncological results of percutaneous radiofrequency ablation for intrahepatic cholangiocarcinoma.

19. Positron emission tomography/computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma

21. Impact of radiological response and pattern of progression in patients with HCC treated by atezolizumab-bevacizumab

22. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial

29. Supplementary Figures 1 - 2 from Identification of Serum Proton NMR Metabolomic Fingerprints Associated with Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis

30. Supplementary Figure 1 from Serum Proteoglycans as Prognostic Biomarkers of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis

31. Data from Serum Proteoglycans as Prognostic Biomarkers of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis

32. Supplementary Table 1 from Serum Proteoglycans as Prognostic Biomarkers of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis

33. Sulfatase 2 Along with Syndecan 1 and Glypican 3 Serum Levels are Associated with a Prognostic Value in Patients with Alcoholic Cirrhosis-Related Advanced Hepatocellular Carcinoma

36. Cyclin A2/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress

38. Impact of sarcopenia on tumor response and survival outcomes in patients with hepatocellular carcinoma treated by trans-arterial (chemo)-embolization

39. ESM-1 expression in stromal cells is predictive of recurrence after radiofrequency ablation in early hepatocellular carcinoma

40. EASL and AASLD recommendations for the diagnosis of HCC to the test of daily practice

44. Impact of Extended Use of Ablation Techniques in Cirrhotic Patients with Hepatocellular Carcinoma: A Cost-Effectiveness Analysis

49. Health-related quality of life in locally advanced hepatocellular carcinoma treated by either radioembolisation or sorafenib (SARAH trial)

Catalog

Books, media, physical & digital resources